Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;47(11):2041-2043.
doi: 10.1111/ced.15347. Epub 2022 Aug 27.

Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics

Maruška Marovt  1 , Petra Deželak  2 , Robert Ekart  3 , Pij B Marko  1
Affiliations

Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics

Maruška Marovt et al. Clin Exp Dermatol. 2022 Nov.

Abstract

The effect of psoriasis treatment with biologics on the efficacy of COVID-19 vaccines is largely unknown. Our study aimed to evaluate antibody response against SARS-CoV-2 following two doses of BNT162b2 (Pfizer/BioNTech vaccine) in patients with psoriasis receiving biologic monotherapy, and compare it with that of healthy controls.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of antibody titres in patients with psoriasis receiving biologic therapy and healthy controls; column charts representing mean antibody titres in binding antibody units (BAU)/mL. Antibody titres were significantly lower in patients as compared with controls (1024.4 ± 870.3 vs. 3055.8 ± 2450.9 BAU/mL; P < 0.001). The difference in titres between different treatment groups [tumour necrosis factor inhibitors (TNFi), interleukin (IL)‐12/23 inhibitors (IL‐12/23i), IL‐17 inhibitors (IL‐17i) and IL‐23 inhibitors (IL‐23i)] was not significant (P = 0.11).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Waldman RA, Grant‐Kels JM. Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID‐19 vaccine dose: a critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations. J Am Acad Dermatol 2021; 85: 1113–16. - PMC - PubMed
    1. Armstrong AW. Pathophysiology, clinical presentation, and treatment of psoriasis. A review. JAMA 2020; 323: 1945–60. - PubMed
    1. Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines 2020; 8: 769. - PMC - PubMed
    1. Al‐Janabi A, Littlewood Z, Griffiths CEM et al. Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease. Br J Dermatol 2021; 185: 646–8. - PMC - PubMed
    1. Geisen UM, Berner DK, Tran F et al. Immunogenicity and safety of anti‐SARS.CoV‐2 mRNA vaccine in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021; 80: 1306–11. - PMC - PubMed